TRANDOLAPRIL 1 MG
TRANDOLAPRIL : 1 MG · DIN 02525046 · SANIS HEALTH INC
Health Canada status: MARKETED
What is TRANDOLAPRIL?
TRANDOLAPRIL 1 MG contains TRANDOLAPRIL : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02525046, held by SANIS HEALTH INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Nov-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRANDOLAPRIL used for?
Treatment of Mild to Moderate Essential Hypertension; Treatment Following Acute Myocardial Infarction in clinically stable patients with left ventricular dysfunction.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02525046 |
|---|---|
| Brand name | TRANDOLAPRIL |
| Generic / active ingredient | TRANDOLAPRIL : 1 MG |
| Manufacturer | SANIS HEALTH INC |
| Strength | 1 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA10 TRANDOLAPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Nov-2022 |
| Original market date | 2022-11-10 00:00:00 |
How is it administered?
Hypertension: 1-2 mg once daily (max 4 mg). Post-MI: Start at 0.5 mg, titrate to 4 mg once daily. Renal/Hepatic impairment: Start at 0.5 mg daily.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to STORAGE AND STABILITY section).
How is it supplied?
Not explicitly detailed in provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section).
Contraindications
Pregnancy/nursing; hypersensitivity to ACE inhibitors; history of angioedema; combination with sacubitril/valsartan, aliskiren, or ARBs in specific patients; renal artery stenosis.
Warnings and precautions
Risk of hypotension, angioedema (can be fatal), hyperkalemia, and neutropenia/agranulocytosis. Dual blockade of RAAS increases risk of hypotension and renal failure.
Is TRANDOLAPRIL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PRO DOC LIMITEE, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09AA10 TRANDOLAPRIL. 25 of 40 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-TRANDOLAPRIL | 0.5 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02471868 |
| AURO-TRANDOLAPRIL | 1 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02471876 |
| AURO-TRANDOLAPRIL | 2 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02471884 |
| AURO-TRANDOLAPRIL | 4 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02471892 |
| MAVIK | 0.5 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02231457 |
| MAVIK | 1 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02231459 |
| MAVIK | 2 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02231460 |
| MAVIK | 4 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02239267 |
| PMS-TRANDOLAPRIL | 0.5 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02357755 |
| PMS-TRANDOLAPRIL | 1 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02357763 |
Who else supplies TRANDOLAPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRANDOLAPRIL appears in 156 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.